Chapter 2 of 25
Oral cavity cancer
This starts in the mobile tongue, floor of mouth, inner cheeks, gums, hard palate or other mouth lining. A persistent ulcer, patch, lump, bleeding or reduced tongue movement can be a warning. Tobacco, smokeless tobacco, areca nut and alcohol are relevant risks, although cancer can occur without them. Examination and biopsy establish the diagnosis; CT or MRI helps assess depth, bone and nodes. Spread often involves neck nodes. Surgery is commonly central for resectable disease, with additional treatment based on pathology. Depth of invasion, margins and node findings matter. Reconstruction and rehabilitation support chewing, swallowing and clear speech.
Oropharyngeal cancer
The oropharynx includes the tonsils, base of tongue, soft palate and throat walls. Symptoms may be throat discomfort, swallowing pain, one-sided ear pain or a neck lump, sometimes with a small hidden primary tumour. High-risk HPV is an important cause, alongside tobacco-related disease. Endoscopy, biopsy, appropriate HPV testing and imaging guide care. Neck-node spread may occur early. Depending on extent and function, treatment may use radiation with or without systemic therapy or selected transoral surgery followed by risk-adapted treatment. HPV association affects staging and prognosis but does not eliminate the need for treatment.
Laryngeal cancer
The larynx contains the vocal cords and helps protect breathing. Cancer starting on a vocal cord may cause persistent hoarseness relatively early; cancers above or below the cords may present differently. Tobacco and alcohol are important risks. Flexible laryngoscopy assesses the cords, including their movement; biopsy and imaging establish extent. Nodal risk varies by the precise subsite. Early lesions may be treated with endoscopic surgery or radiotherapy. More advanced cancers may need chemoradiotherapy or laryngectomy. Baseline swallowing, airway safety, cartilage involvement and realistic function matter as much as the wish to preserve the voice box.
Hypopharyngeal cancer
The hypopharynx is the lower throat beside and behind the voice box, leading into the esophagus. Increasing swallowing difficulty, pain, weight loss or a neck lump may be presenting symptoms. Tobacco and alcohol are common risks. Endoscopy with biopsy and scans assess the primary and cervical nodes; submucosal spread can make assessment challenging. Treatment may involve chemoradiotherapy or surgery and postoperative treatment. Nutrition, aspiration risk and speech rehabilitation need early attention. Stage, resectability, general fitness and the possibility of retaining useful swallowing influence both treatment and prognosis.
Nasopharyngeal carcinoma
This begins behind the nose rather than in the visible mouth. A neck lump, one-sided blocked ear or hearing change, persistent nasal blockage or nosebleeds may lead to diagnosis. Epstein–Barr virus is associated with many cases; geographic and familial factors also matter. Nasal endoscopy and biopsy, MRI and relevant EBV testing are useful. Nodes behind the throat and on both sides of the neck may be involved. Radiotherapy is central; chemotherapy is added in appropriate stages, sometimes before chemoradiotherapy. Its staging, systemic treatments and monitoring are distinct from the usual oral-cavity SCC pathway.
Sinonasal cancers
These begin in the nasal cavity or air-filled sinuses. Persistent one-sided blockage, blood-stained discharge, facial numbness or swelling, or new eye symptoms need evaluation. Certain occupational exposures, including wood and leather dust, are associated with particular tumour types. Endoscopy, biopsy and CT/MRI define the histology and relationship to the orbit and skull base. SCC, adenocarcinoma, olfactory neuroblastoma and other rarer cancers need different plans. Surgery and radiation are common components, with systemic treatment selected by histology and extent. Vision, facial function and specialised reconstruction may be important considerations.
Salivary gland cancers
These arise in major glands near the ear or jaw or in minor glands throughout the mouth and throat. A persistent gland lump, pain, numbness or facial weakness can prompt investigation. Most salivary lumps are not cancer, but new weakness deserves early attention. Ultrasound-guided needle sampling, specialist pathology and imaging help distinguish many different histologies. Surgery is often the main treatment for localised disease; radiotherapy depends on risk factors. Grade, nerve involvement, margins and distant spread are relevant. Selected advanced cancers may benefit from testing for HER2, androgen receptor or gene fusions such as NTRK.
Lip cancer
A persistent lip sore, crusting, bleeding or thickening should be examined. Ultraviolet exposure is especially relevant to the outer lip; tobacco is also a risk. The exact surface matters: cutaneous or vermilion lip lesions may follow a skin-cancer classification, whereas inner mucosal lip lesions belong to the oral-cavity pathway. Biopsy establishes the type. Small cancers are often treated locally with surgery or radiotherapy, with node assessment when appropriate. Treatment seeks both tumour control and preservation of lip seal, speech, eating and appearance. Do not assign staging merely from the word “lip”.
Neck-node cancer with an unknown primary
Sometimes a needle sample from a neck node shows cancer before its starting point can be found. This is called an unknown or occult primary. The assessment may include specialist examination, endoscopy, imaging, PET-CT in selected circumstances and tissue-based HPV or EBV tests. Selected patients need targeted tonsil or base-of-tongue procedures. A cystic node is not automatically benign. Treatment depends on the node pathology, extent and likely origin and can still have curative intent. Surgery, radiotherapy and systemic treatment are chosen to control disease while avoiding unnecessary treatment to unrelated structures.
Using the site-specific pathways
Ask the team to write the exact anatomical origin and pathology name. A word such as “throat” is helpful in conversation but too broad to choose treatment. This guide’s early-stage, locally advanced and special-types chapters expand these pathways. Future dedicated guides should link to these distinctions; until available, use these existing chapters and the authoritative site-specific patient resources below.
References and evidence review
- NCI PDQ: Lip and Oral Cavity Cancer Treatment (2025)
- NCI PDQ: Oropharyngeal Cancer Treatment (2025)
- NCI PDQ: Nasopharyngeal Cancer Treatment (2025)
- NCI: Head and Neck Cancer patient resources
- AAO-HNS: Evaluation of the Neck Mass in Adults, guideline (2017)
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.